RESUMEN
Multiple prevention therapy has gained importance for the prevention and treatment of sexually transmitted diseases, especially HIV/AIDS. Antiretroviral drugs encapsulated in nanoparticles have been developed for efficient delivery of the drugs to the vaginal surface. Lactoferrin nanoparticles (LFNPs) encapsulating anticancer or antiretroviral drugs are found to be promising agents to specifically deliver drugs at the target sites. Recent studies indicate that the bioavailability is higher for antiretroviral drugs delivered by LFNPs than when the drugs are administered alone. Although LFNP-mediated drug delivery via the oral or vaginal route for the treatment of HIV/AIDS is promising, the effect of such administrations is not well studied. Drug-loaded LFNPs when administered to rats by the vaginal route did not show any effect on the reproductive performance, fertility, and postnatal development. Oral administration of drug-loaded LFNPs caused a significant decrease in litter size, whereas the reproductive performance and postnatal development remained normal. In our model system, the results indicate that vaginal administration of drug-loaded LFNPs appears safer and can be projected for the delivery of antiretroviral agents via the vaginal route. Abbreviations: LFNPs: lactoferrin nanoparticles; STIs: sexually transmitted diseases infections; NPs: nanoparticles; LF: lactoferrin; DL-LFNPs: drug loaded lactoferrin nanoparticles; MPT: multiple prevention techniques.
Asunto(s)
Antirretrovirales/administración & dosificación , Benzoxazinas/administración & dosificación , Curcumina/administración & dosificación , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Administración Intravaginal , Alquinos , Animales , Ciclopropanos , Evaluación Preclínica de Medicamentos , Femenino , Lactoferrina , Nanopartículas , Embarazo , RatasRESUMEN
To investigate the effectiveness of Ingaron (interferon-) in the treatment of HPV infection associated with sexually transmitted infections, the authors analyzed the scientific literature on the association of human papillomavirus infection with other viral and microbial pathogens. A clinical case of the association of human papillomavirus infection, urogenital infections (urogenital chlamydia and genital herpes) and localized scleroderma penis is described. The results of integrated therapy of diseases with the help of Interferon-gamma have been presented. According to the literature, up to 70-80% of HPV infections are associated with microbial (opportunistic, obligate pathogens) and viral infectious agents. Chronic inflammation caused by bacterial and viral associations destroys the immune system and it leads to the ineffectiveness of the therapy. Pathogenic therapy of sexually transmitted infections in combination with interferon-gamma (Ingaron) contributes to the eradication of bacterial pathogens, prevention of viral STI recurrence and elimination of high oncogenic risk types of HPV. Thus, we can reasonably infer that Ingaron (interferon-) alleviates the initial immune disturbances, improves the effectiveness of the treatment and may be recommended for treating HPV infection associated with sexually transmitted infections.
Asunto(s)
Antivirales/uso terapéutico , Interferón gamma/uso terapéutico , Infecciones por Papillomavirus/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Adulto , Infecciones por Chlamydia/complicaciones , Infecciones por Chlamydia/tratamiento farmacológico , Coinfección , Herpes Genital/complicaciones , Herpes Genital/tratamiento farmacológico , Humanos , Masculino , Enfermedades Urogenitales Masculinas/complicaciones , Enfermedades Urogenitales Masculinas/tratamiento farmacológico , Esclerodermia Localizada/complicaciones , Esclerodermia Localizada/tratamiento farmacológicoRESUMEN
In this investigation, a therapeutic co-delivery hydrogel system is developed to provide effective HIV prophylaxis, alongside the prevention and/or treatment of candidiasis. Two components-a HIV reverse transcriptase inhibitor, tenofovir, and a cationic macromolecular antifungal agent derived from a vitamin D-functionalized polycarbonate (VD/BnCl (1:30))-are formulated into biodegradable vitamin D-functionalized polycarbonate/PEG-based supramolecular hydrogels. The hydrogels exhibit thixotropic properties and can be easily spread across surfaces for efficient drug absorption. Sustained release of tenofovir from the hydrogel is observed, where approximately 85% tenofovir is released within 3 h. VD/BnCl (1:30) does not impede drug diffusion from the hydrogel as the drug release profiles are similar with and without the polycation. Antimicrobial efficacy studies indicate that the hydrogels kill C. albicans efficiently with a minimum bactericidal concentration (MBC) of 0.25-0.5 g L(-1) . These hydrogels also eradicate C. albicans biofilm effectively at 4× MBC. When human dermal fibroblasts (as model mammalian cells) are treated with these hydrogels, cell viability remains high at above 80%, demonstrating excellent biocompatibility. When applied topically, this dual-functional hydrogel can potentially prevent HIV transmission and eliminate microbes that cause infections in the vulvovagina region.
Asunto(s)
Antifúngicos/administración & dosificación , Antivirales/administración & dosificación , Sistemas de Liberación de Medicamentos , Hidrogeles/administración & dosificación , Hidrogeles/química , Animales , Biopelículas/efectos de los fármacos , Candida albicans/efectos de los fármacos , Células Cultivadas , Evaluación Preclínica de Medicamentos/métodos , Fibroblastos/efectos de los fármacos , Humanos , Hidrogeles/síntesis química , Hidrogeles/farmacología , Ratones , Pruebas de Sensibilidad Microbiana , Cemento de Policarboxilato/química , Polietilenglicoles/química , Polietilenglicoles/farmacología , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Tenofovir/administración & dosificación , Tenofovir/química , Vitamina D/administración & dosificación , Vitamina D/químicaRESUMEN
BACKGROUND: The ethnic usage of exotics and indigenous problem plants is a highly debated topic, as legislative requirements over-shadow their potential medicinal value, particularly to treat sexually transmitted infections (STIs). Limited information exists regarding their medicinal value among the Bapedi. OBJECTIVES: To ascertain the importance of exotics and indigenous problem plants in the treatment of STIs, a major global primary health care challenge. METHODS: A field observation and semi-structured questionnaire focussing on species diversity, types of STIs treated and medicinal preparation as well as application was used to collect data from 34 traditional healers. RESULTS: Seven exotics and three indigenous problem species were identified. These species were used to treat four STIs; with Catharanthus roseus illustrating its dominance in the treatment of gonorrhoea. Some medicinal species used by Bapedi traditional healers have been validated through scientific research or through their extensive use by various cultures in South Africa and other parts of Africa. To the best of our knowledge Alternanthera pungens, Caesalpinia decapetala, Cinnamomum verum, and Citrullus lanatus are reported for the first time in the treatment of the investigated STIs. CONCLUSIONS: Exotic and indigenous problem species constitute an important component of the STIs treatment protocol. Their utilization by Bapedi cautions against the narrow-minded approach of indiscriminate eradication, as these species can play a significant role in the primary health care needs of socio-economic vulnerable people.
Asunto(s)
Población Negra , Medicina Tradicional , Fitoterapia , Preparaciones de Plantas/uso terapéutico , Enfermedades Bacterianas de Transmisión Sexual/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Humanos , Plantas Medicinales , Sudáfrica , Encuestas y CuestionariosRESUMEN
OBJECTIVES: We conducted a randomized clinical trial to test an integrated behavioral intervention designed to enhance using HIV treatment as prevention by improving medication adherence, reducing risks for other sexually transmitted infections, and minimizing risk compensation beliefs. METHODS: Individuals living with HIV/AIDS (n = 436) participated in a randomized clinical trial testing an intensive behavioral intervention aimed at reducing HIV transmission risks compared with an attention control condition. We used unannounced pill counts to monitor antiretroviral therapy adherence and computerized interviews to measure risk behaviors. RESULTS: The integrated transmission risk reduction intervention demonstrated increased antiretroviral therapy adherence and less unprotected intercourse with nonseroconcordant partners at 3- and 6-month follow-ups as well as fewer new sexually transmitted infections diagnosed over the 9-month follow-up period (adjusted odds ratio = 3.0; P < .05; 95% confidence interval = 1.01, 9.04). The integrated intervention also reduced behavioral risk compensation beliefs. CONCLUSIONS: A theory-based integrated behavioral intervention can improve HIV treatment adherence and reduce HIV transmission risks. HIV treatment as prevention should be bundled with behavioral interventions to maximize effectiveness.
Asunto(s)
Fármacos Anti-VIH/administración & dosificación , Terapia Conductista/métodos , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/prevención & control , Cooperación del Paciente , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/prevención & control , Adulto , Femenino , Georgia/epidemiología , Infecciones por VIH/transmisión , Humanos , Masculino , Distribución de Poisson , Conducta de Reducción del Riesgo , Enfermedades Virales de Transmisión Sexual/transmisión , Resultado del Tratamiento , Carga ViralRESUMEN
Almost three decades have elapsed since researchers identified HIV as the cause of AIDS, with current estimates from UNAIDS that 33.4 million adults were living with HIV/AIDS in 2008. Two-thirds of this burden of disease is in Sub-Saharan Africa, and 60% of those infected are women. The disease still remains incurable and current prevention strategies including abstinence, male/female condom use and male circumcision are only partially effective. New strategies to curb the epidemic are urgently needed. Scientists are diligently exploring HIV prevention methods that are safe, effective and affordable. These new biological interventions include oral pre-exposure prophylaxis using oral antiretroviral (ARV) drugs, ARV treatment in HIV-infected persons to reduce transmission and topical ARV-based microbicide formulations.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Antiinfecciosos/uso terapéutico , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/prevención & control , Salud de la Mujer , Adulto , África del Sur del Sahara/epidemiología , Animales , Fármacos Anti-VIH/administración & dosificación , Antiinfecciosos/administración & dosificación , Quimioprevención , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Femenino , Infecciones por VIH/epidemiología , Infecciones por VIH/transmisión , Humanos , Macaca , Masculino , Ratones , Prevalencia , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/epidemiología , Enfermedades Virales de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/transmisión , Resultado del TratamientoRESUMEN
In the last decade, cases of sexually-transmitted infections (STIs) have progressively increased in Europe. The reasons for this increase are unclear, but may involve changes in social behavior, migration and international travel, coupled with the emergence of risk groups that have not been taken into sufficient consideration to date. The routine use of molecular diagnostic techniques for many of these infections has solved many problems of sensitivity and the suitability of samples for microbiological diagnosis: non-invasive samples can be used, which has undoubtedly contributed to the increase in the number of cases. Moreover, molecular methods have also been introduced for antibiotic and antiviral susceptibility testing, as well as for molecular characterization of clinical isolates. All of these factors, together with the approval of the vaccine against the human papillomavirus, have changed the landscape of STIs across Europe.
Asunto(s)
Enfermedades de Transmisión Sexual , Antiinfecciosos/uso terapéutico , Europa (Continente)/epidemiología , Femenino , Humanos , Infestaciones por Piojos/tratamiento farmacológico , Infestaciones por Piojos/transmisión , Masculino , Pruebas de Sensibilidad Microbiana/métodos , Técnicas de Diagnóstico Molecular , Conducta Sexual , Enfermedades de Transmisión Sexual/diagnóstico , Enfermedades de Transmisión Sexual/tratamiento farmacológico , Enfermedades de Transmisión Sexual/epidemiología , Enfermedades de Transmisión Sexual/prevención & control , Enfermedades Bacterianas de Transmisión Sexual/diagnóstico , Enfermedades Bacterianas de Transmisión Sexual/tratamiento farmacológico , Enfermedades Bacterianas de Transmisión Sexual/epidemiología , Enfermedades Bacterianas de Transmisión Sexual/prevención & control , Enfermedades Virales de Transmisión Sexual/diagnóstico , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Enfermedades Virales de Transmisión Sexual/epidemiología , Enfermedades Virales de Transmisión Sexual/prevención & control , ViajeAsunto(s)
Antivirales/química , Materiales Biocompatibles/química , Química Farmacéutica/métodos , Emulsiones/química , Glicéridos/administración & dosificación , Glicéridos/química , Pomadas/química , Administración Tópica , Antivirales/análisis , Materiales Biocompatibles/análisis , Evaluación Preclínica de Medicamentos , Elasticidad , Emulsiones/análisis , Glicéridos/análisis , Humanos , Ensayo de Materiales , Pomadas/análisis , Enfermedades Virales de Transmisión Sexual/tratamiento farmacológico , Estadística como Asunto , ViscosidadRESUMEN
AIDS: Recent developments on new anti-HIV agents and drugs for opportunistic infections are highlighted. Information is provided on the infusion inhibitor T-20; DuPont's second generation non-nukes, DPC 961 and DPC 963; Papirine (PEN203) for the human papilloma virus; Sporanox for treating fungal infections; and the antiretroviral protein, lysozyme. In addition, information is given on a plant found in the Bolivian rainforest that may contain compounds to prevent HIV infection by blocking the enzyme, integrase. Other promising new drugs addressed at the 6th Conference on Retroviruses and Opportunistic Infections are listed in a table. Contact information for US clinical trials is provided.^ieng